Last reviewed · How we verify
Inhaled Loxapine
Inhaled loxapine is a rapid-acting antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce acute agitation.
Inhaled loxapine is a rapid-acting antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce acute agitation. Used for Acute agitation associated with schizophrenia or bipolar disorder.
At a glance
| Generic name | Inhaled Loxapine |
|---|---|
| Also known as | ADASUVE |
| Sponsor | Alexza Pharmaceuticals, Inc. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Loxapine is a dibenzoxazepine antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. The inhaled formulation delivers the drug directly to the lungs for rapid systemic absorption, enabling faster onset of action compared to oral formulations, making it suitable for acute agitation management in psychiatric settings.
Approved indications
- Acute agitation associated with schizophrenia or bipolar disorder
Common side effects
- Sedation
- Dysarthria
- Tremor
- Extrapyramidal symptoms
- Throat irritation
Key clinical trials
- Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
- Staccato Prochlorperazine Single Dose PK Study (PHASE1)
- Outcomes of Antipsychotic Medication Used in the Emergency Department
- Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication (PHASE1)
- Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting (PHASE4)
- A Study of Staccato Loxapine (ADASUVE®) for Inhalation (PHASE3)
- Staccato Loxapine Thorough QT/QTc Study (PHASE1)
- Staccato Loxapine Pulmonary Safety in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled Loxapine CI brief — competitive landscape report
- Inhaled Loxapine updates RSS · CI watch RSS
- Alexza Pharmaceuticals, Inc. portfolio CI